|
|
Vaccine Detail
|
Vaccinia-Tyrosinase Vaccine |
| Vaccine Information |
- Vaccine Name: Vaccinia-Tyrosinase Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007122
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Tyrosinase
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Melanoma Cancer (NCT00019734). A vaccine consisting of recombinant vaccinia virus, based on the modified vaccinia virus Ankara (MVA) that encodes the melanoma-associated antigen tyrosinase. Vaccination with vaccinia-tyrosinase may stimulate the host immune system to mount a cytotoxic T-cell response against tumor cells expressing tyrosinase. Tyrosinase is a melanoma-specific differentiation agent that catalyzes the synthesis of the melanin precursor L-3,4-dihydroxyphenylalanine (L-DOPA) (NCIT_C2531).
|
| Host Response |
|
|
| References |
NCIT_C2531: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2531]
NCT00019734: [https://clinicaltrials.gov/show/NCT00019734/]
|
|
